Scarica l'app Stockscreener
92.51
1.67%
1.52
Oruka Therapeutics Inc Borsa (ORKA) Ultime notizie
Oruka Therapeutics Files $1 Billion Mixed Shelf - marketscreener.com
Oruka Therapeutics Inc aStock (AORKA) Price Prediction for 2026 to 2031 - Bybit
Show Me The Money: ORKA Makes A Splash With A 500%+ Gain; More Catalysts Ahead - RTTNews
Oruka (ORKA) Outlook: Finishes 4.40% Lower at $104.86 in the Current Update; Level Watch: Support at $99.62 and Resistance at $110.10 Frame the Range at the CloseFRAMA Signal - Vinanet
RTW Investments, LP Expands Oruka Therapeutics (ORKA) Stake with Strategic Add - GuruFocus
Oruka (ORKA) Earnings Snapshot: The Available Earnings Metric Delivers a Miss in the Available Record; Post-Report: Shares Finish 3.00% Down for the Current SessionEarnings Cycle Outlook - Vinanet
Preferred dividends of Oruka Therapeutics, Inc. – HAM:HQ1 - TradingView
Oruka Therapeutics, Inc. Income Statement – HAM:HQ1 - TradingView
Oruka Therapeutics (ORKA) Is Up 8.0% After Wider Q2 Net LossesHas The Bull Case Changed? - simplywall.st
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Oruka Therapeutics CMO Joana Goncalves sells $782,882 in stock - Investing.com
Joana Goncalves Sells 7,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 52-Week HighWhat's Next? - MarketBeat
ORKA Q2 2026 Earnings: Wider Loss Reflects R&D Investment as Pre-Revenue Biotech Advances PipelineEarnings Power Value - Vinanet
Biotech Stocks At 52-Week HighsETON +44%, DXCM, ORKA, CON, ATAI - RTTNews
Oruka Therapeutics (NASDAQ:ORKA) Cut to "Sell" at Wall Street Zen - MarketBeat
LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $175 - Moomoo
ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94% - Stocktwits
Oruka Therapeutics stock hits 52-week high at 109.56 USD By Investing.com - Investing.com South Africa
Oruka Therapeutics GC Paul Quinlan sells $5.64m stock By Investing.com - Investing.com Canada
Oruka Therapeutics GC Paul Quinlan sells $5.64m stock - Investing.com
Oruka Therapeutics senior vice president Arjun Agarwal sells $1.06m By Investing.com - Investing.com Australia
Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) SVP Sells 10,000 Shares of Stock - MarketBeat
Oruka Therapeutics senior vice president Arjun Agarwal sells $1.06m - Investing.com
Oruka Therapeutics Insider Sold Shares Worth $5,641,409, According to a Recent SEC Filing - marketscreener.com
Oruka Therapeutics Insider Sold Shares Worth $1,066,572, According to a Recent SEC Filing - marketscreener.com
Oruka Therapeutics (ORKA): Venrock group reports 7.4% ownership stake - Stock Titan
ORKA (ORKA) insider Paul Quinlan files to sell 71,000 shares via option exercise - Stock Titan
Viking Global group discloses 1.50M Oruka (ORKA) shares on amended 13G - Stock Titan
Oruka Therapeutics stock hits 52-week high at 109.56 USD - Investing.com
Oruka Therapeutics (ORKA) gains 5.2% stake holder with 3.14M shares - Stock Titan
Handelsbanken Fonder AB Purchases Shares of 160,900 Oruka Therapeutics, Inc. $ORKA - MarketBeat
Sei Investments Co. Raises Position in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Oruka Therapeutics (ORKA) On Its Earnings Miss And Whether The Valuation Still Holds - Sahm
A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $133 to $180 - Moomoo
Dimensional Fund Advisors LP Makes New Investment in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Capital World Investors (ORKA) reports 5.6% beneficial stake in Oruka Therapeutics - Stock Titan
Wedbush Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $165 - Moomoo
Oruka Therapeutics (ORKA) Is Up 10.9% After Wider-Than-Expected Q2 Loss From R&D InvestmentHas The Bull Case Changed? - simplywall.st
Oruka Therapeutics' (ORKA) "Buy" Rating Reaffirmed at Guggenheim - MarketBeat
Oruka Therapeutics' (ORKA) Outperform Rating Reiterated at Wedbush - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Given "Buy" Rating at BTIG Research - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month HighStill a Buy? - MarketBeat
ORUKA THERAPEUTICS INC : LEERINK PARTNERS RAISES TARGET PRICE TO $179 FROM $162 - Bitget
Oruka Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Oruka Therapeutics Q2 Loss Widens - marketscreener.com
Oruka Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Oruka Therapeutics Q2 EPS of $(0.55) misses estimates - scanx.trade
Oruka Therapeutics (NASDAQ:ORKA) Issues Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
Earnings Flash (ORKA) Oruka Therapeutics Posts Q2 Loss $0.55 a Share, vs. FactSet Est of $0.53 Loss - marketscreener.com
Oruka Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Oruka Therapeutics reports Q2 2026 results: $1.1B cash; net loss $41.2M in quarter - TradingView
The Manufacturers Life Insurance Company Acquires 11,205 Shares of Oruka Therapeutics, Inc. $ORKA - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):